公司資料
Kezar Life Sciences 股價、新聞與催化劑
- 股票代碼:
- KZR
- 交易所:
- NASDAQ
- 產業:
- Life Science Tools
- 所在地:
- United States
股票表現
7.29 USD (-0.95%)
收盤價
最後更新: 2026年5月8日
53.9M USD
市值
股價為何變動
目前無法取得 KZR 的收盤價變動背景。
公司概覽
Immunology-Focused Biotechnology Company
Kezar Life Sciences has focused on small-molecule therapies for immune-mediated diseases. Following portfolio reductions and operational restructuring, its principal remaining development asset is zetomipzomib.
Zetomipzomib Mechanism
Zetomipzomib is a selective inhibitor of the immunoproteasome, a protein-degradation complex enriched in immune cells. By modulating immunoproteasome activity, the candidate is intended to reduce inflammatory signaling and pathogenic immune-cell activity without broadly suppressing the constitutive proteasome.
Autoimmune Hepatitis Program
The lead indication is relapsed or refractory autoimmune hepatitis, a chronic inflammatory liver disease commonly managed with long-term corticosteroids and other immunosuppressive drugs. Kezar has sought a development strategy that could demonstrate disease control while reducing steroid exposure.
PORTOLA Clinical Evidence
The randomized Phase 2a PORTOLA study evaluated zetomipzomib in patients inadequately controlled by standard therapy. Results supported clinically meaningful steroid-sparing remissions and provided the clinical basis for discussions about a potential global Phase 2b program.
Focused Strategic Position
Kezar discontinued its KZR-261 trial and sold its Sec61 discovery assets, concentrating remaining value on zetomipzomib and associated partnership rights. The company has also been evaluating strategic alternatives for the asset and the broader business.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。